Literature DB >> 33638130

Intranasal drug delivery for treatment of Alzheimer's disease.

Leonor C Fonseca1,2, João A Lopes1,2, João Vieira1,2, Cláudia Viegas1,2, Cláudia S Oliveira1,2, Rafael P Hartmann1,2, Pedro Fonte3,4,5.   

Abstract

The Alzheimer's disease is a neurodegenerative condition with severe consequences interfering with patient quality of life. It is characterized as a progressive and irreversible brain disorder hampering memory and thinking, affecting the capacity to perform daily tasks leading to physical and cognitive incapacitation. The conventional treatment occurs by the oral route, but it presents relevant drawbacks such as low bioavailability, fast metabolism, limited brain exposure, and undesirable side effects. The intranasal route has been proposed as a promising alternative to deliver drugs and improve the Alzheimer's disease treatment. Still, there is not a clear alternative delivery system available in the market with advantageous bioavailability and safety. The aim of this review is to perform an overview on the strategies for drug intranasal delivery for Alzheimer's disease treatment. The advantages and disadvantages of this delivery route and the delivery systems developed so far are discussed. A special focus is given on the use of permeation enhancers, the types of intranasal drug delivery devices, as well as possible toxicity concerns.

Entities:  

Keywords:  Blood-brain barrier; Central nervous system; Nanoparticle; Neurodegenerative; Permeation enhancer; Protein

Mesh:

Substances:

Year:  2021        PMID: 33638130     DOI: 10.1007/s13346-021-00940-7

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  41 in total

1.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Nanoparticle transport across in vitro olfactory cell monolayers.

Authors:  Oihane Gartziandia; Susana Patricia Egusquiaguirre; John Bianco; José Luis Pedraz; Manoli Igartua; Rosa Maria Hernandez; Véronique Préat; Ana Beloqui
Journal:  Int J Pharm       Date:  2015-12-22       Impact factor: 5.875

3.  Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats.

Authors:  Christine Dufes; Jean-Christophe Olivier; Frédéric Gaillard; Afsaneh Gaillard; William Couet; Jean-Marc Muller
Journal:  Int J Pharm       Date:  2003-04-14       Impact factor: 5.875

Review 4.  Mechanism of intranasal drug delivery directly to the brain.

Authors:  Tyler P Crowe; M Heather West Greenlee; Anumantha G Kanthasamy; Walter H Hsu
Journal:  Life Sci       Date:  2017-12-22       Impact factor: 5.037

Review 5.  Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies.

Authors:  Daniel S Auld; Tom J Kornecook; Stéphane Bastianetto; Rémi Quirion
Journal:  Prog Neurobiol       Date:  2002-10       Impact factor: 11.685

6.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Authors:  Willemijn J Jansen; Rik Ossenkoppele; Dirk L Knol; Betty M Tijms; Philip Scheltens; Frans R J Verhey; Pieter Jelle Visser; Pauline Aalten; Dag Aarsland; Daniel Alcolea; Myriam Alexander; Ina S Almdahl; Steven E Arnold; Inês Baldeiras; Henryk Barthel; Bart N M van Berckel; Kristen Bibeau; Kaj Blennow; David J Brooks; Mark A van Buchem; Vincent Camus; Enrica Cavedo; Kewei Chen; Gael Chetelat; Ann D Cohen; Alexander Drzezga; Sebastiaan Engelborghs; Anne M Fagan; Tormod Fladby; Adam S Fleisher; Wiesje M van der Flier; Lisa Ford; Stefan Förster; Juan Fortea; Nadia Foskett; Kristian S Frederiksen; Yvonne Freund-Levi; Giovanni B Frisoni; Lutz Froelich; Tomasz Gabryelewicz; Kiran Dip Gill; Olymbia Gkatzima; Estrella Gómez-Tortosa; Mark Forrest Gordon; Timo Grimmer; Harald Hampel; Lucrezia Hausner; Sabine Hellwig; Sanna-Kaisa Herukka; Helmut Hildebrandt; Lianna Ishihara; Adrian Ivanoiu; William J Jagust; Peter Johannsen; Ramesh Kandimalla; Elisabeth Kapaki; Aleksandra Klimkowicz-Mrowiec; William E Klunk; Sebastian Köhler; Norman Koglin; Johannes Kornhuber; Milica G Kramberger; Koen Van Laere; Susan M Landau; Dong Young Lee; Mony de Leon; Viviana Lisetti; Alberto Lleó; Karine Madsen; Wolfgang Maier; Jan Marcusson; Niklas Mattsson; Alexandre de Mendonça; Olga Meulenbroek; Philipp T Meyer; Mark A Mintun; Vincent Mok; José Luis Molinuevo; Hanne M Møllergård; John C Morris; Barbara Mroczko; Stefan Van der Mussele; Duk L Na; Andrew Newberg; Agneta Nordberg; Arto Nordlund; Gerald P Novak; George P Paraskevas; Lucilla Parnetti; Gayan Perera; Oliver Peters; Julius Popp; Sudesh Prabhakar; Gil D Rabinovici; Inez H G B Ramakers; Lorena Rami; Catarina Resende de Oliveira; Juha O Rinne; Karen M Rodrigue; Eloy Rodríguez-Rodríguez; Catherine M Roe; Uros Rot; Christopher C Rowe; Eckart Rüther; Osama Sabri; Páscual Sanchez-Juan; Isabel Santana; Marie Sarazin; Johannes Schröder; Christin Schütte; Sang W Seo; Femke Soetewey; Hilkka Soininen; Luiza Spiru; Hanne Struyfs; Charlotte E Teunissen; Magda Tsolaki; Rik Vandenberghe; Marcel M Verbeek; Victor L Villemagne; Stephanie J B Vos; Linda J C van Waalwijk van Doorn; Gunhild Waldemar; Anders Wallin; Åsa K Wallin; Jens Wiltfang; David A Wolk; Marzena Zboch; Henrik Zetterberg
Journal:  JAMA       Date:  2015-05-19       Impact factor: 56.272

7.  Genetics of Alzheimer disease.

Authors:  A T Rao; A J Degnan; L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-28       Impact factor: 3.825

8.  Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.

Authors:  Vincent Doré; Victor L Villemagne; Pierrick Bourgeat; Jurgen Fripp; Oscar Acosta; Gael Chetélat; Luping Zhou; Ralph Martins; Kathryn A Ellis; Colin L Masters; David Ames; Oliver Salvado; Christopher C Rowe
Journal:  JAMA Neurol       Date:  2013-07       Impact factor: 18.302

9.  Acetylcholinesterase inhibitors: pharmacology and toxicology.

Authors:  Mirjana B Colović; Danijela Z Krstić; Tamara D Lazarević-Pašti; Aleksandra M Bondžić; Vesna M Vasić
Journal:  Curr Neuropharmacol       Date:  2013-05       Impact factor: 7.363

Review 10.  Intranasal treatment of central nervous system dysfunction in humans.

Authors:  Colin D Chapman; William H Frey; Suzanne Craft; Lusine Danielyan; Manfred Hallschmid; Helgi B Schiöth; Christian Benedict
Journal:  Pharm Res       Date:  2012-11-08       Impact factor: 4.200

View more
  1 in total

Review 1.  Recent Advances in the Treatment of Alzheimer's Disease Using Nanoparticle-Based Drug Delivery Systems.

Authors:  Prashant Poudel; Soyeun Park
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.